AKT1 and ovarian carcinoma: Recently, miransertib (ARQ 092) an oral, allosteric, selective pan-AKT inhibitor was identified, trialled in patients with ovarian cancers bearing an activating AKT1 variant and reported showing favourable efficacy and side effects [244, 245].